No treatment
Mild disease (no hypoxia)
No risk factors for progression to severe disease
Consider hydroxychloroquine
Mild diseas (no hypoxia)
Risk factors for progression to severe disease
Remdesivir (randomized controlled trial)
Hydroxychloroquine (if remdesivir not feasible)
Moderate to severe disease
Hospitalized, non-ICU level care
Appropriate ARDS management
ARDS-targeted therapies (mesenchymal stem or stromal cells)
Remdesivir (randomized controlled trial or compassionate use)
ICU level care
(regardless of intubation status)
Treatment
Scenario
Biotechnology
Zuckerberg San Francisco General Hospital COVID-19 Treatment Guidelines (as of March 17, 2020)